Metformin also exhibits an anti-tumor effect by regulating programmed death-1(PD-1)/programmed death-ligand 1(PD-L1) immunosuppressive checkpoints, which may involve ERS and adenosine monophosphate-activated protein kinase (AMPK) pathways (19, 20). Here, CD274 is linked to neoplasm.